Sensor device for attachment to injection device

Abstract

To provide a supplementary device configured to be releasably attached to a distal end of a drug delivery device.SOLUTION: A supplementary device configured to be releasably attached to a distal end of a drug delivery device, the supplementary device comprising primary electronics 24, a non-contact acceleration sensor 110 and a low power processor 112. The non-contact acceleration sensor is directed towards a proximal end of the drug delivery device, and the low power processor is configured to: receive signals output from the non-contact acceleration sensor; based on the signals, determine that an outer needle cap of the drug delivery device has been removed; and, in response to determining that an outer needle cap of the drug delivery device has been removed, send a wake-up signal to the primary electronics of the supplementary device.SELECTED DRAWING: Figure 3

Description

[Technical field]

[0001] The present disclosure relates to a device configured to hold a medication delivery device including an injection device, syringe, or cartridge, detect a user gesture, and wake up the device from a low power mode when a user gesture is detected. [Background technology]

[0002] There are a variety of diseases that require regular treatment by injection of medication. Such injections can be performed using injection devices, which are administered either by medical personnel or by the patient themselves.

[0003] Injection devices (i.e. devices capable of delivering medication from a pharmaceutical container) typically fall into two categories - manual devices and injection devices. In manual devices - the user must provide mechanical energy to drive the fluid through the needle. This is typically done by some form of button / plunger that the user must continuously press during the injection.

[0004] Injection devices aim to make it easier for patients to administer therapy by injection themselves. Current therapies administered by self-administered injections include drugs for diabetes (both insulin and newer GLP-1 class drugs), migraines, allergies, hormone therapy, blood thinners, etc. Injection devices can be used to deliver single doses of certain life-saving drugs. For example, they are often prescribed to people at risk of anaphylaxis. They are often used in the military to protect personnel from chemical warfare agents. Alternatively, injection devices are used to administer drugs according to prescribed treatment schedules to people suffering from multiple sclerosis, rheumatoid arthritis, anemia, etc.

[0005] An injection device is a device that completely or partially replaces the actions involved in parenteral drug delivery from a standard syringe. These actions can include inserting a needle into the patient's skin, injecting the medication, removing the needle, shielding the needle, and preventing reuse of the device. This overcomes many of the disadvantages of manual devices. It reduces the force required by the user, hand vibration, and the possibility of delivering an incomplete dose. Triggering can be accomplished by a number of means, for example, a trigger button or the action of the needle reaching the injection depth. In some devices, the energy to deliver the fluid is provided by a spring.

[0006] Injection devices can be disposable or single-use devices that can only be used to deliver one dose of medication and must be discarded after use. Other types of injection devices can be reusable. They are usually configured to allow the user to load and remove a standard syringe. Reusable injection devices can be used to perform multiple parenteral drug deliveries, with the syringe being discarded and removed from the injection device after consumption. The syringe may be packaged with additional components to provide additional functionality. In a typical scenario, the treatment of a disease can be performed by the patient himself by using the injection device to inject a dose of medication, for example daily, weekly, biweekly, or monthly. Summary of the Invention [Problem to be solved by the invention]

[0007] Reusable add-on devices suitable for use with syringes are known that monitor the dose delivered by the syringe (and provide other information to the user). What is needed is a way to minimize the power consumption of such additional devices. [Means for solving the problem]

[0008] According to a first aspect of the present disclosure, there is provided an auxiliary device configured to be releasably attached to a distal end of a drug delivery device, the auxiliary device including: a main electronic circuit; a non-contact acceleration sensor located on or in the auxiliary device, the non-contact acceleration sensor being oriented toward a proximal end of the drug delivery device; and a low power processor configured to receive a signal output from the non-contact acceleration sensor; determine based on the signal that an outer needle cap of the drug delivery device has been removed; and send an activation signal to the main electronic circuit of the auxiliary device in response to determining that the outer needle cap of the drug delivery device has been removed.

[0009] In some embodiments, the auxiliary device further includes a memory readable by the low power processor, the memory storing one or more acceleration profiles.

[0010] Some embodiments include a memory storing software for comparing a signal output from the non-contact acceleration sensor to one or more acceleration profiles.

[0011] In some embodiments, the auxiliary device is configured to operate in a machine learning mode in which one or more acceleration profiles are updated based on signals output from the non-contact acceleration sensor.

[0012] In some embodiments, each of the one or more acceleration profiles is associated with a different type of drug delivery device.

[0013] In some embodiments, a first of the one or more acceleration profiles includes data indicative of a rapid acceleration in the proximal direction followed by a rapid deceleration in the proximal direction.

[0014] In some embodiments, a first of the one or more acceleration profiles further includes data indicative of a substantially constant velocity between a rapid proximal acceleration and a rapid proximal deceleration.

[0015] In some embodiments, a first of the one or more acceleration profiles further includes data indicating that the rapid deceleration in the proximal direction continues until the total change in velocity indicates movement in the distal direction.

[0016] In some embodiments, a second of the one or more acceleration profiles includes data indicative of a sudden acceleration in the proximal direction followed by an abrupt stop.

[0017] In some embodiments, the non-contact acceleration sensor is positioned to detect the movement of a user's hand as the hand removes the outer needle cap.

[0018] In some embodiments, the auxiliary device further includes a position sensor located on or within the auxiliary device, the position sensor being oriented toward the proximal end of the drug delivery device and configured to output a signal indicative of the position and / or orientation of the user's hand and / or the drug delivery device.

[0019] In some embodiments, the non-contact acceleration sensor is an electromagnetic reflective sensor.

[0020] In some embodiments, the non-contact acceleration sensor is an optical sensor or an infrared sensor.

[0021] In some embodiments, the position sensor is a passive infrared sensor or an accelerometer.

[0022] In some embodiments, the auxiliary device further includes a lock sensor, the lock sensor configured to output a signal indicating whether the auxiliary device is attached to the drug delivery device.

[0023] In some embodiments, the auxiliary device further includes a wireless unit configured to transmit data to one or more external devices.

[0024] In some embodiments, the auxiliary device further includes an electronic display configured to vary its display of information in response to signals output by the position and / or orientation sensor.

[0025] According to a second aspect of the present disclosure, there is provided a method for operating an auxiliary device configured to be releasably attached to a distal end of a drug delivery device, the method comprising: providing a non-contact acceleration sensor located on or in the auxiliary device and directed toward a proximal end of the drug delivery device to output a signal; receiving a signal output from the non-contact acceleration sensor at a low power processor; determining, based on the signal, that an outer needle cap of the drug delivery device has been removed, by the low power processor; and sending an activation signal to a main electronic circuit of the auxiliary device in response to determining that the outer needle cap of the drug delivery device has been removed.

[0026] In some embodiments, the method further includes the low power processor: accessing one or more acceleration profiles; comparing a signal output from the non-contact acceleration sensor to the one or more acceleration profiles; and determining, based on the comparison, whether an outer needle cap of the drug delivery device has been removed.

[0027] According to a third aspect, there is provided a system comprising an auxiliary device according to any one of claims 1 to 16 and a drug delivery device. [Brief description of the drawings]

[0028] [Figure 1A] FIG. 2 is a side view of the injection device. [Figure 1B] FIG. 1B is a side view of the injection device of FIG. 1A with the cap removed. [Figure 2A] FIG. 1C is a perspective view of an auxiliary device releasably attached to the injection device of FIGS. 1A and 1B. [Figure 2B]FIG. 1C is a perspective view of an auxiliary device releasably attached to the injection device of FIGS. 1A and 1B. [Diagram 3] FIG. 2C is a side view of the auxiliary device of FIGS. 2A and 2B and an attached injection device, illustrating some of the main internal and external components of the auxiliary device. [Figure 4] FIG. 2C is a side view of the auxiliary device of FIGS. 2A and 2B and an attached injection device according to a further embodiment. [Diagram 5] 5 is a flow chart illustrating exemplary operations of FIGS. 2A, 2B, 3, and 4. [Figure 6] 1 illustrates the display of the auxiliary device in use, showing the various states of the device; DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0029] In the following, embodiments of the present disclosure are described with reference to a pen-type injector. The invention is not limited to such applications and can be deployed equally well with other types of drug delivery devices such as syringes, prefilled syringes, needleless injectors, and inhalers.

[0030] An injection device 10 (also referred to herein as a drug delivery device 10) according to an embodiment will now be described with reference to Figures 1A and 1B. In some embodiments, the injection device 10 is a single-use injection device 10, also known as an auto-injector. In some other embodiments, the injection device 10 is a reusable injection device, or an injection device that can be used to inject several doses before being discarded. The injection device 10 has a proximal end P and a distal end D. The proximal end P is directed towards an injection site on a patient during injection, and the distal end D is directed away from the injection site.

[0031] Injection device 10 includes a body 9 and a cap 12 (also referred to herein as an outer needle cap 12 or ONC 12). Body 9 includes an outer housing 11. Outer housing 11 is an elongated tube. Outer housing 11 includes a cartridge or syringe holder (not shown) that supports a cartridge or syringe 18 containing a liquid medicament 16. In the following description, reference is made to cartridge 18 being supported by the cartridge holder (not shown). Cartridge 18 is shown in dashed lines in FIG. 1B.

[0032] The outer housing 11 also contains a dispensing mechanism (not shown) for causing dispensing of the medication 16 during injection.

[0033] A hollow needle 17 communicates with the interior volume of a cartridge or syringe 18 and acts as a conduit for the liquid medicament 16 during injection. The needle 17 and cartridge 18 are in fixed positions relative to each other and to the body 9. A stopper, plunger, piston or bung 14 is movable within the cartridge 18 so as to expel the medicament contained within the cartridge 18 through the needle 17 under the action of a dosing mechanism.

[0034] The dispensing mechanism is mechanically coupled to the piston 14 of the cartridge 18. The dispensing mechanism is configured to move the piston in an axial proximal direction along the cartridge 18 to dispense the medicament 16 through the needle 17. The dispensing mechanism includes components that cooperate to apply a force to the piston 14 in response to an activation input provided by a user. In this case, the activation input that triggers the application of the force to the piston 14 is received via a dose dispensing button 13 located at the distal end of the injection device 10. The dispensing mechanism is mechanically coupled to the dose dispensing button 13.

[0035] The body 9 also includes a cap support 19 at the proximal end of the outer housing 11. The cap support is concentric with the outer housing 11 and may have a smaller diameter than it. The cap support 19 extends from the proximal end of the housing 11. The ONC 12 is received over the cap support 19 to close the proximal end of the body 9 and cover the needle 17. The ONC 12 includes a cylindrical wall 21 and an end wall 22. When the ONC 12 is positioned on the body 9 as shown in FIG. 1A, the inner surface of the cylindrical wall 21 abuts in a tight abutting relationship against the outer surface of the cap support 19 such that the ONC 12 is held thereon in the installed position. The ONC 12 may thus be held on the cap support by frictional abutment.

[0036] The cap support 19 may include one or more protrusions, e.g., one or more annular flanges, on its outer surface. The ONC 12 may include one or more corresponding recesses, e.g., annular recesses, on its inner surface. These configurations interlock or cooperate when the ONC 12 is attached to the injection device 10 to increase the frictional force that holds the ONC 12 on the injection device 10, thereby increasing the force required to remove the ONC 12 from the injection device 10.

[0037] To inject the medication 16, the ONC 12 is removed from the device 10 by the user, resulting in the configuration shown in Figure 1B. The proximal end of the injection device 10 is then pressed against an injection site on a patient, which may be the user or another person. The user then activates the dosing button 13. This causes the dosing mechanism to push the piston 14 out of the cartridge 18, through the needle 17 and into the patient's injection site.

[0038] Some other injection devices (not shown) may include an activation sleeve in the form of an elongated cap support 19 that extends beyond the tip of the needle 17 prior to activation of the injection device. In this case, the activation input that triggers application of a force to the piston 14 is received by movement of the activation sleeve in a distal direction, which movement is configured to trigger operation of the injection device. The ONC 12 is received over the activation sleeve to close the proximal end of the body 9. Such injection devices may not have a dosing button.

[0039] After a user injects a dose of medication into their skin, it is advantageous for the needle to remain in place for a short period of time (e.g., 5-20 seconds) to allow the medication to diffuse away from the injection site due to the action of the user's blood flow. This is often referred to as the "dwell time." Removing the needle too soon after injection can result in the medication being pushed away from the injection site, thus resulting in the user not receiving the full dose.

[0040] The cartridge 18 is transparent and the housing 11 is provided with a window 15 that coincides with the cartridge 18 to allow viewing of the medicament 16 contained within the cartridge 18. A user of the injection device can inspect it to determine whether the entire amount of medicament 16 has been expelled from the cartridge 18 during an injection.

[0041] A label is provided on the surface of the housing 11. The label includes information 100 about the medication contained within the injection device 10, including information identifying the medication. The information 100 identifying the medication may be in the form of text. The information 100 identifying the medication may also be in the form of a color. The information 100 identifying the medication may also be coded in a bar code, a QR code, etc. The information 100 identifying the medication may also be in the form of a black and white pattern, a color pattern, or a shade of color.

[0042] Fig. 2a is a schematic diagram of an embodiment of an auxiliary device 2 releasably attached to the injection device 10 of Fig. 1. The auxiliary device 2 is suitable for use with the injection device shown in Figs. 1A and 1B as well as other types of injection devices as discussed above. The auxiliary device 2 includes a housing 20 configured to surround the housing 11 of the injection device 10 of Fig. 1 such that the injection device 10 is at least partially retained within the auxiliary device 2, but is nevertheless removable from the auxiliary device 2, for example when the injection device 10 is empty and requires replacement. The injection device 10 and the auxiliary device 2 may optionally include cooperating alignment arrangements to ensure that the auxiliary device 2 is properly oriented and positioned relative to the injection device 10.

[0043] The auxiliary device 2 has an attachment mechanism 8 for securing and detaching the auxiliary device 2 to the injection device 10. The attachment mechanism 8 may be rotatable relative to the main body 20 of the auxiliary device 2 between a locked position and an unlocked position. Figure 2a shows the attachment mechanism 8 in a locked position. Figure 2b shows the attachment mechanism 8 in an unlocked position. In some other embodiments, the auxiliary device 2 can be secured to the injection device 10 by a simple friction fit.

[0044] The information is displayed via a display unit 4 of the auxiliary device 2. The display unit 4 may be a color LCD screen. The display unit may be a touch-sensitive screen. For example, the display unit 4 shows the user of the auxiliary device 2 the time and date of the next scheduled injection. During operation of the injection device 10, the auxiliary device 2 may also display information to assist the user, as described in more detail below.

[0045] The auxiliary device 2 includes at least one user input 6, such as a touch-sensitive button. The user input 6 may include one or more LEDs that are formed in a ring around the button and / or that illuminate the entire button. These user inputs 6 may allow the user to turn the auxiliary device 2 on / off, trigger an action (e.g., establish a link or pairing with another device and / or trigger the transmission of information from the auxiliary device 2 to another device), or confirm something.

[0046] Figure 3 illustrates some of the main internal and external components of the auxiliary device 2 as attached to the injection device 10 shown in Figures 1A and 1B. Externally, the auxiliary device 2 includes a display unit 4, a user input 6, an attachment mechanism 8, and a battery compartment 102.

[0047] The auxiliary device 2 includes internally a main electronic circuit 24. The main electronic circuit 24 includes at least a processor 25 and a memory. The main electronic circuit 24 may include both a program memory and a main memory. The processor 25 may be, for example, a microprocessor, a digital signal processor (DSP), an application specific integrated circuit (ASIC), a field programmable gate array (FPGA), etc. The processor 25 executes the program code (e.g., software or firmware) stored in the program memory and uses the main memory, for example, to store intermediate results. The main memory may also be used to store a logbook about the dispenses / injections performed. The program memory may be, for example, a read-only memory (ROM), and the main memory may be, for example, a random access memory (RAM).

[0048] The auxiliary device 2 also includes a wireless unit 28 configured to transmit and / or receive information to / from another device in a wireless manner. Such transmission can be based, for example, on radio or optical transmission. In some embodiments, the wireless unit 28 is a Bluetooth transceiver. Alternatively, the wireless unit 28 may be replaced or supplemented by a wired unit configured to transmit and / or receive information to / from another device in a wired manner, for example via a cable or fiber connection. When data is transmitted, the units of the data (values) to be transmitted can be explicitly or implicitly defined. For example, for insulin doses, International Units (IU) may always be used or alternatively the units used may be transmitted explicitly, for example in coded form. The transmitted data also includes a timestamp associated with the injection.

[0049] The auxiliary device 2 also includes an audio module 104 configured to provide acoustic feedback to a user of the auxiliary device 2. Both the wireless unit 28 and the audio module 104 may be coupled to and controlled by the main electronics 24. The auxiliary device 2 optionally includes a lock sensor 106 configured to detect whether the attachment mechanism is in a locked or unlocked position.

[0050] The auxiliary device 2 may also include an optical sensor 26 for reading information 100 identifying the medication. The information 100 identifying the medication may be a color or a different color of the housing 11 of the injection device. The color of the drug may be the color of a label attached to an area of ​​the housing or to the housing. In these embodiments, the optical sensor 26 may be a simple photometer configured to detect the color. In some other embodiments, the drug identifying information 100 may be a QR code or other similar coded information, and the optical sensor 26 may be a camera or a QR code reader. In addition, one or more light sources may be provided to improve the reading of the optical sensor 26. The light sources may provide light of a particular wavelength or spectrum to improve the detection of the color by the optical sensor 26. The light sources may be positioned in such a way that undesired reflections, e.g. due to curvature of the housing 11, are avoided or reduced. In an exemplary embodiment, the optical sensor 26 is a camera unit configured to detect a code 100 (e.g. a barcode, which may be, e.g., a one-dimensional or two-dimensional barcode) associated with the injection device and / or the drug contained therein. The code 100 may be located, for example, on the housing 11 or on a drug container included in the injection device 10, just to name a few examples. The code 100 may indicate, for example, the type of injection device and / or the drug, and / or further characteristics (e.g. an expiration date). The code 100 may be a QR code 100. QR codes are typically black and white, so no color detection is required on the part of the optical sensor 26. This makes the optical sensor 26 simple and cheap to manufacture.

[0051] The processor 25 can be configured to check the information 100 read by the optical sensor 26 against pre-stored information to verify that the user is injecting the correct medication. If the processor 25 does not recognize the information 100 or recognizes the information 100 as indicating a different medication than the user should be receiving at that time, the auxiliary device 2 generates a warning signal. The warning signal can include a word or graphic displayed on the display unit 4 or a sound generated by the audio module 104. Alternatively or additionally, the auxiliary device 2 can send the warning signal to an external device via the wireless unit 28.

[0052] The auxiliary device 2 includes a non-contact acceleration sensor 110 (also referred to herein as a non-contact sensor or a first non-contact sensor). The non-contact acceleration sensor 110 is located on or in the auxiliary device and is oriented toward the proximal end of the drug delivery device. For example, the non-contact acceleration sensor 110 can be disposed on a surface of the auxiliary device 2 or can be held within the auxiliary device 2. Depending on the sensor technology used, the non-contact acceleration sensor 110 may be covered with a transparent window to prevent tampering or damage.

[0053] The non-contact acceleration sensor 110 is configured to output a signal indicative of a change in the velocity of a user's hand relative to the sensor 110 when the user removes the ONC 12 from the injection device 10. The non-contact acceleration sensor 110 is sometimes referred to as a non-contact sensor because it can detect changes in the velocity of the user's hand without contact between the sensor 110 and the user's hand. The non-contact acceleration sensor 110 may be located such that it does not or cannot detect movement of the ONC 12 itself.

[0054] The auxiliary device 2 also includes a low power processor 112. The non-contact acceleration sensor 110 is in communication with the low power processor 112 and may be at least partially controlled by the low power processor 112. Both the low power processor 112 and the non-contact acceleration sensor 110 may draw power from a battery (not shown) and are designed to draw only a very small current such that the auxiliary device operates in a low power mode.

[0055] The auxiliary device 2 may also include a memory (not shown) that stores one or more acceleration profiles. The one or more acceleration profiles may be used to capture the ONC 12. The acceleration profile represents a typical user's hand movements during removal. In some embodiments, the memory is a separate component, and in some embodiments, the memory is integral with the low power processor 112 or integral with the non-contact acceleration sensor 110. In other words, the low power processor 112 may be pre-programmed with at least one acceleration profile or may have access to at least one acceleration profile that represents a typical cap removal movement.

[0056] The low-power processor 112 is coupled to the main electronics 24 and is configured to exchange signals with the processor 25 of the main electronics 24. The low-power processor 112 is configured to receive the signal output by the non-contact acceleration sensor 110 and to determine a change in the velocity of the user's hand relative to the non-contact acceleration sensor 110. The low-power processor 112 is configured to determine whether the received signal is indicative of a typical cap removal movement of the user's hand. The low-power processor 112 may do this by checking the received signal against one or more acceleration profiles. If the low-power processor 112 determines that the received signal is indicative of a typical cap removal movement of the user's hand, the low-power processor 112 sends a wake-up signal to the main electronics 24.

[0057] A typical hand movement of a user when removing the ONC 12 involves overcoming static frictional forces that stick the ONC 12 to the injection device 10. These forces can be increased by configurations such as flanges, recesses, and undercuts as previously described. The user therefore increases the force pulling on the ONC 12 until the frictional forces are overcome and the ONC is suddenly released from the injection device 10. This results in a rapid proximal acceleration that is detected by the non-contact acceleration sensor 110. It takes some time for the user to react to the release of the ONC 12. In reacting, the user quickly reduces the force applied to the ONC 12, which results in a rapid (proximal) deceleration that is detected by the non-contact acceleration sensor 110. There can be periods of approximately constant velocity (or more gentle acceleration or deceleration) between the rapid proximal acceleration and the rapid proximal deceleration. The first acceleration profile can represent the ONC cap removal process described above and can be stored in memory as previously described.

[0058] In some cases, when the user reacts to the sudden acceleration caused by the release of the frictional connection, the user moves the ONC 12 backward, i.e., in a generally distal direction, a short distance toward the injection device before stopping the ONC 12. In other words, the sudden deceleration in the proximal direction continues until the total change in speed indicates a change in direction from proximal to distal before the ONC 12 is stopped again. The second acceleration profile may represent this change in direction of the ONC cap removal process.

[0059] Different users may remove the ONC 12 differently. For example, some users may remove the ONC 12 less carefully. This results in a sudden acceleration as the frictional forces holding the ONC 12 and the rubber needle shield of the syringe to the injection device 10 are overcome, followed by a period of approximately constant velocity (or more gentle acceleration) until the user's hand moves out of range or viewing angle of the non-contact acceleration sensor 110. In other words, there is a characteristic sudden acceleration followed by an abrupt stop (due to the user's hand moving out of range of the sensor 110). The abrupt stop may be indicated by the end of the signal received by the processor 112 from the non-contact acceleration sensor (i.e., loss of signal from the acceleration sensor may indicate a sudden or abrupt stop). The third acceleration profile may represent this less careful ONC cap removal process.

[0060] The memory also includes a measurement of the variation in the static friction between the ONC 12 and the injection device 10, and the time required for use. Multiple variants of the acceleration profiles described above can also be stored that account for differences in how users perform each individual uncapping process.

[0061] Only when the low power processor 112 determines that the ONC 12 is removed does it send a wake-up signal to the main electronics 24. This has the advantage of minimizing power consumption in the auxiliary device 2, because the low power processor 112 and non-contact acceleration sensor 110 are configured to draw less power than the main electronics.

[0062] In FIG. 4, an alternative auxiliary device 2 according to a further embodiment is illustrated. In addition to the components already described with reference to FIG. 3, the auxiliary device 2 of FIG. 4 includes a position sensor 114. The position sensor 114 can be coupled to and at least partially controlled by the low-power processor 112. The position sensor 114 is located on or in the auxiliary device and is directed toward the proximal end of the drug delivery device. The position sensor 114 is configured to output a signal indicative of the position and / or orientation of the user's hand. For example, it may be possible to determine from the signal output by the position sensor 114 whether the user is using his / her left or right hand to grasp the ONC 12. The memory may store individual acceleration profiles for removal of the ONC 12 with the left and right hands, and thus the signal from the position sensor 114 may be used to inform the low-power processor 112 which acceleration profile to check. In some embodiments, the memory may store individual orientation profiles associated with specific orientations of the ONC when grasped with the user's left or right hand. In this case, the position sensor 114 may be a passive infrared sensor, a capacitive displacement sensor, or a three-axis electronic sensor (e.g., a three-axis accelerometer or a three-axis compass). The position sensor 114 may include one or more of these types of sensors.

[0063] After the low-power processor 112 determines whether the user is using their left or right hand to hold the ONC 12, the low-power processor 112 can use this information to control the orientation of the information displayed on the display 4. For example, if the ONC 12 is being held in the user's left hand, the low-power processor 112 can send a signal to the display 4 to cause the display 4 to display information to the user in a format that is easily readable by the user in this (i.e., "left-handed") orientation. However, if the injection device 10 is being held in the user's right hand, the low-power processor 112 can send a signal to the display 4 to cause the display 4 to display information to the user in a format that is easily readable by the user in this (i.e., "right-handed") orientation. This improves the readability of the display and improves the ease of use of the device.

[0064] In some embodiments, the position sensor 114 can be configured to determine the orientation of the auxiliary device 10 and thus the orientation of the injection device 10. When a user grasps the injection device 10 to remove the ONC 12, the user typically holds the injection device 10 in a particular orientation. The position sensor 114 can be configured to detect the orientation and send a signal to the low power processor 112. Similarly, when the injection device is used (i.e., an injection is performed), the injection device is held in a particular orientation by the user. The position sensor 114 can be configured to detect this orientation and send a signal to the low power processor 112.

[0065] The low power processor 112 is configured to receive the signal output by the non-contact acceleration sensor 110 and to determine the orientation of the injection device. The low power processor 112 is configured to determine whether the received signal indicates that the pen is oriented in a manner such that a user is about to remove the cap, or in a manner immediately prior to the start of an injection. The low power processor 112 may do this by checking the received signal against one or more orientation profiles. If the low power processor 112 determines that the received signal indicates a typical orientation, the low power processor 112 sends a wake-up signal to the main electronics 24. If the low power processor 112 determines that the received signal indicates that the injection device 10 is not in a typical orientation (e.g., it does not correlate with a particular profile), the low power processor 112 may not send a wake-up signal to the main electronics 24, or the low power processor 112 may send a signal indicating that the injection device 10 is not in a typical orientation.

[0066] The non-contact acceleration sensor 110 can take several different forms. For example, an electromagnetic sensor operates based on electromagnetic reflection. The sensor 110 can use visible or infrared light and use the Doppler shift of the light reflected from the user's moving hand to detect acceleration. Alternatively, microwave or radio waves may be used. These have the advantage of being inherently lower energy than visible light and can pass through opaque sections of the housing 20 of the auxiliary device 2. Alternatively, the non-contact acceleration sensor 110 may be embodied as a capacitive displacement sensor. The proximity of the user's hand changes the capacitance detected by the sensor. In some other embodiments, a capacitive displacement sensor may be used as a combination of the non-contact acceleration sensor 110 and the absolute position sensor 114.

[0067] The auxiliary device 2 can also be placed into a machine learning mode in which it can create or update an acceleration profile. For example, a user or technician can use the touch screen 4 to enter a learning mode for the non-contact acceleration sensor. The user or technician can then repeatedly remove and replace the ONC 12 of the injection device 10 under instructions from the display 4 of the auxiliary device 2. In this way, the auxiliary device 2 can refine the acceleration profile to better fit real-world conditions, or create a new acceleration profile that better fits the way a particular user removes the ONC 12.

[0068] The auxiliary device 2 may include several other components and perform several other functions. For example, the housing 20 of the auxiliary device 2 may hold at least one further non-contact sensor (not shown) arranged adjacent to the outer housing 11 of the injection device 10 and to detect the movement of one or more movable components within the injection device. The movement of the movable components may be associated with the activation of the injection device and the ejection of the medicament. Examples of movable components are (i) a spring, e.g. a pre-compressed spring that is decompressed during the ejection of the medicament, (ii) an element configured to move between two different configurations depending on whether the injection device is in a pre-activation or post-activation state, (iii) a slidable element that moves longitudinally, e.g. from a distal end to a proximal end of the injection device 10, during the ejection of the medicament, or (iv) a rotatable sleeve configured to rotate during the ejection of the medicament.

[0069] The main electronics 24 can receive signals from at least one further non-contact sensor, infer an operating state of the injection device 10 and cause information regarding the timing of the operation of the injection device 10 to be stored in a main memory and / or transmitted to an external device via the wireless unit 28. The main electronics can also cause information regarding the operating state of the injection device 10 to be displayed on the display 4 of the auxiliary device 2. For example, the display 4 can indicate whether the injection device is in a pre-activation state, a current injection state, a holding (or "dwell time") state or a post-activation state.

[0070] FIG. 5 is a flow chart illustrating operations that the auxiliary device 2 can perform.

[0071] In step 500, the low power processor 112 receives a signal from the non-contact acceleration sensor 110. In step 502, one or more acceleration profiles are accessed. As previously described, the low power processor 112 or the non-contact acceleration sensor 110 can be pre-programmed with the acceleration profiles. Alternatively, the low power processor 112 can access memory to read the acceleration profiles. In step 504, the signal output from the non-contact acceleration sensor is compared to the one or more acceleration profiles to determine a match. The match does not necessarily have to be exact, and tolerances may be set for various sections of each acceleration profile. In step 506, the low power processor 112 determines that the outer needle cap of the drug delivery device has been removed based on the comparison.

[0072] Steps 500 to 506 may be an uninterrupted process whenever the auxiliary device 2 is attached to the injection device 10, for example whenever the lock sensor 106 indicates that the attachment mechanism 8 is locked. If the low power processor 112 determines that the outer needle cap of the drug delivery device has been removed, then in step 508 the low power processor 112 sends a wake-up signal to the main electronics 24 of the auxiliary device. The main electronics 24 may then perform their functions of monitoring the movement of components within the injection device 10, determining the status and displaying on the display 4.

[0073] In some embodiments, there may be further operational steps performed by the auxiliary device 2. The low power processor 112 may determine whether the ONC 12 is removed based on signals received from both the non-contact acceleration sensor 110 and the position sensor 114. For example, if the signals received from both the non-contact acceleration sensor 110 and the position sensor 114 indicate that the ONC 12 is removed, the low power processor 112 may determine that the ONC 12 is removed and send a wake-up signal to the main electronics 24 of the auxiliary device. However, if the low power processor 112 receives only one signal from either the non-contact acceleration sensor 110 or the position sensor 114, the low power processor 112 may determine that the ONC 12 is not removed and may not send a wake-up signal to the main electronics 24 of the auxiliary device. These additional processing operations may form part of steps 506 and 508 or may be separate steps or series of steps.

[0074] In this manner, by using both the signal received from the non-contact acceleration sensor 110 and the signal received from the position sensor 114 (i.e., receiving information from two sources), a more accurate determination of whether the ONC 12 has been removed can be made, thereby reducing power consumption.

[0075] In some embodiments, after the low power processor 112 determines that the ONC 12 of the drug delivery device has been removed, the low power processor 112 can start a timer (e.g., a countdown timer). If the low power processor 112 does not receive a signal from the device components indicating that the activation sleeve or piston 14 is operating within a period set by the timer (e.g., 1 minute), the low power processor 112 can send a signal to the display 4. This can occur when the user removes the ONC 12 but has not started the injection procedure. In this case, there is a risk of the needle clogging because the drug contained within the needle bore may come into contact with air and, for example, dry up (i.e., due to evaporation). Thus, when the display 4 receives a signal indicating this condition, the display 4 can display a warning condition to remind the user that the ONC 12 has been removed and prompt the user to begin an injection or replace the ONC 12, thereby reducing the amount of time the ONC 12 is removed from the device and helping to prevent needle clogging. Alternatively or additionally, in some embodiments, the user may also be prompted to begin an injection or replace the cap by an audible signal. (eg, the low power processor 112 may send a signal to a speaker or an alarm).

[0076] In some embodiments, the timer period may be predefined and stored in the program memory of the auxiliary device. Alternatively or additionally, the timer period may be modified by a user and stored in the main memory of the device, or may be created or updated using a machine learning mode and stored in the main memory. The processor 112 may further be configured to use a signal received from a sensor (not shown) that detects movement of the actuation sleeve or piston 14, indicating that an injection is occurring.

[0077] FIG. 6 illustrates the display 4 of the device 2 showing eight different syringe pen states (600-607). State 600 may be displayed on the display 4 after removal of the ONC 12 is detected (as discussed above) and prior to the start of an injection. As can be seen, the display 4 shows several segments, bars, or blocks 115 that can be individually illuminated. The display may alternatively show other means of representing a change in time, such as an analog clock or shaded areas of varying size. Before the start of an injection, the blocks 115 occupy most of the display 4, indicating that the drug delivery device contains a drug and that the injection has not yet begun.

[0078] During injection, the amount of drug contained within the device 2 decreases, which is detected by the processor 112 receiving a signal from a sensor detecting the movement of the actuation sleeve or piston 14. This can be indicated by a change in the number of blocks 115 occupying the display 4. For example, during injection, the number of blocks 115 decreases (as shown in state 601). In some embodiments, the display 4 starts with all blocks 115 illuminated, indicating that the drug delivery device is unused. The blocks 115 are then sequentially removed from right to left until no blocks are displayed, indicating that the drug delivery device is empty. The display may be dynamic during the injection process, for example the blocks 115 may flash.

[0079] After the user injects a quantity of medication into his / her skin, the needle is advantageously left in place for a short period of time (e.g., 5-20 seconds). This is known as the "dwell time" or "hold time". This allows the medication to diffuse away from the injection site under the action of the user's blood flow. Removing the needle too soon after the injection can result in the medication being pushed out of the injection site, thus resulting in the user not receiving the full dose. As already mentioned, the processor 112 can use the change in the signal received from the sensor in the actuation sleeve or piston to determine that an injection is being performed. The processor 112 can infer that the injection is complete when the signal received from the sensor stops changing. This detection can therefore be used as a trigger to display an indication on the display unit 4 to the user instructing them to leave the needle of the injection device 10 in the injection site for a predetermined length of time. This indication can be of any suitable form, for example a timer that counts up or down, or a graphic that expands / shrinks or is filled or faded. The indicator may count down over a period of time, as shown in states 602, 603, 604, 605, and 606. For example, the indicator may count down over a period of five seconds. This may be indicated by a decrease in the number of blocks 115 occupying the display. At the end of the dwell time, as shown in state 607, the display may change to inform the user that the injection is complete. The user may also be informed by an audible signal that the injection is complete. Other methods of indication (e.g., vibration) may be used.

[0080] The display may show other information to the user besides the states shown in Figure 6. For example, the display may show the user when the injection device should be replaced (e.g. when it is empty).

[0081] The terms "drug" or "medicament" are used interchangeably herein to describe a pharmaceutical formulation containing one or more active pharmaceutical ingredients or their pharma- ceutically acceptable salts or solvates, and optionally a pharma- ceutically acceptable carrier. An active pharmaceutical ingredient ("API"), in its broadest sense, is a chemical structure that has a biological effect on humans or animals. In pharmacology, drugs or medicines are used to treat, cure, prevent, or diagnose diseases or otherwise improve physical or mental well-being. Drugs or medicines can be used for a limited duration or periodically for chronic disorders.

[0082] As described below, drugs or agents may include at least one API or combinations thereof in various types of formulations for the treatment of one or more diseases. Examples of APIs may include small molecules with molecular weights of 500 Da or less, polypeptides, peptides, and proteins (e.g., hormones, growth factors, antibodies, antibody fragments, and enzymes), carbohydrates and polysaccharides, as well as nucleic acids, double-stranded or single-stranded DNA (including naked and cDNA), RNA, antisense nucleic acids such as antisense DNA and RNA, small interfering RNA (siRNA), ribozymes, genes, and oligonucleotides. Nucleic acids may be incorporated into molecular delivery systems such as vectors, plasmids, or liposomes. Mixtures of one or more drugs are also contemplated.

[0083] The drug or agent can be contained in a primary package or "drug container" adapted for use in a drug delivery device. The drug container can be, for example, a cartridge, syringe, reservoir, or other rigid or flexible vessel configured to provide a chamber suitable for storage (e.g., short-term or long-term storage) of one or more drugs. For example, in some cases, the chamber can be designed to store the drug for at least one day (e.g., from one day to at least 30 days). In some cases, the chamber can be designed to store the drug for about one month to about two years. Storage can be at room temperature (e.g., about 20° C.) or at refrigerated temperatures (e.g., from about −4° C. to about 4° C.). In some cases, the drug container can be or include a dual-chamber cartridge configured to separately store two or more components of a pharmaceutical formulation to be administered (e.g., an API and a diluent, or two different drugs), one in each chamber. In such cases, the two chambers of the dual-chamber cartridge can be configured to allow mixing between two or more components prior to and / or during administration to the human or animal body. For example, the two chambers can be configured to be in fluid communication with each other (e.g., via a conduit between the two chambers) and to allow mixing of the two components by a user, if desired, prior to administration. Alternatively or additionally, the two chambers can be configured to allow mixing upon administration of the components to the human or animal body.

[0084] The drugs or agents contained in the drug delivery devices described herein can be used for the treatment and / or prevention of many different types of medical disorders. Examples of disorders include, for example, diabetes or complications associated with diabetes, such as diabetic retinopathy, thromboembolic disorders, such as deep vein thromboembolism or pulmonary thromboembolism. Further examples of disorders are acute coronary syndromes (ACS), angina, myocardial infarction, cancer, macular degeneration, inflammation, hay fever, atherosclerosis and / or rheumatoid arthritis. Examples of APIs and drugs include those listed in handbooks such as Rote Liste 2014 (for example, but not limited to, main groups 12 (antidiabetic agents) or 86 (oncology agents)) and the Merck Index, 15th edition. It is listed in the .

[0085] Examples of APIs for the treatment and / or prevention of type 1 or type 2 diabetes or complications associated with type 1 or type 2 diabetes include insulin, e.g., human insulin, or a human insulin analog or derivative, glucagon-like peptide (GLP-1), a GLP-1 analog or GLP-1 receptor agonist, analog or derivative thereof, a dipeptidyl peptidase-4 (DPP4) inhibitor, or a pharma-ceutically acceptable salt or solvate thereof, or any mixture thereof. As used herein, the terms "analog" and "derivative" refer to a polypeptide having a molecular structure that is formally derivable from the structure of a naturally occurring peptide, e.g., the structure of human insulin, by deletion and / or replacement of at least one amino acid residue present in the naturally occurring peptide and / or by addition of at least one amino acid residue. The added and / or replaced amino acid residue can be either a codable amino acid residue or another naturally occurring residue or a purely synthetic amino acid residue. Insulin analogs are also referred to as "insulin receptor ligands". In particular, the term "derivative" refers to a polypeptide having a molecular structure formally derivable from the structure of a naturally occurring peptide, e.g., the molecular structure of human insulin in which one or more organic substituents (e.g., fatty acids) are attached to one or more of the amino acids. Optionally, one or more amino acids present in the naturally occurring peptide are deleted and / or replaced by other amino acids, including non-codeable amino acids, or amino acids, including non-codeable ones, are added to the naturally occurring peptide.

[0086] Examples of insulin analogues are Gly(A21), Arg(B31), Arg(B32) human insulin (insulin glargine); Lys(B3), Glu(B29) human insulin (insulin glulisine); Lys(B28), Pro(B29) human insulin (insulin lispro); Asp(B28) human insulin (insulin aspart); human insulin in which the proline in position B28 may be replaced by Asp, Lys, Leu, Val or Ala and in which the Lys in position B29 may be replaced by Pro; Ala(B26) human insulin; Des(B28-B30) human insulin; Des(B27) human insulin and Des(B30) human insulin.

[0087] Examples of insulin derivatives are e.g. B29-N-myristoyl-des(B30) human insulin, Lys(B29)(N-tetradecanoyl)-des(B30) human insulin (insulin detemir, Levemir®); B29-N-palmitoyl-des(B30) human insulin; B29-N-myristoyl human insulin; B29-N-palmitoyl human insulin; B28-N-myristoyl-LysB28ProB29 human insulin; B28-N-palmitoyl-LysB28ProB29 human insulin; B30-N-myristoyl-ThrB29LysB30 human insulin. ; B30-N-palmitoyl-ThrB29LysB30 human insulin; B29-N-(N-palmitoyl-gamma-glutamyl)-des(B30) human insulin, B29-N-omega-carboxypentadecanoyl-gamma-L-glutamyl-des(B30) human insulin (insulin degludec, Tresiba®); B29-N-(N-lithocholyl-gamma-glutamyl)-des(B30) human insulin; B29-N-(ω-carboxyheptadecanoyl)-des(B30) human insulin and B29-N-(ω-carboxyheptadecanoyl) human insulin.

[0088] Examples of GLP-1, GLP-1 analogs and GLP-1 receptor agonists include, for example, lixisenatide (Lyxumia®), exenatide (exendin-4, Byetta®, Bydureon®, reon®, a 39 amino acid peptide produced by the salivary glands of the flatfish monster), liraglutide (Victoza®), semaglutide, taspoglutide, albiglutide (Syncria®), dulaglutide (Trulicity®), rExendin-4, CJC-1134-PC, PB-1023 , TTP-054, langrenatide / HM-11260C, CM-3, GLP-1 Erigen, ORMD-0901, NN-9924, NN-9926, NN-9927, Nodexene, Viador-GLP-1, CVX-096, ZYOG-1, ZYD-1, GSK-2374697, DA-3091, MAR-701, MAR709, ZP-2929, ZP-3022, TT-401, BHM-034 、 MOD-6030, CAM-2036, DA-15864, ARI-2651, ARI-2255, exenatide-XTEN and glucagon-Xten.

[0089] An example of an oligonucleotide is, for example, mipomersen sodium (Kynamro®), a cholesterol-lowering antisense therapeutic for the treatment of familial hypercholesterolemia.

[0090] Examples of DPP4 inhibitors are vidagliptin, sitagliptin, denagliptin, saxagliptin, berberine.

[0091] Examples of hormones include pituitary or hypothalamic hormones or regulatory active peptides and their antagonists, such as gonadotropins (follitropin, lutropin, chorion gonadotropin, menotropin), somatropine (somatropin), desmopressin, terlipressin, gonadorelin, triptorelin, leuprorelin, buserelin, nafarelin, and goserelin.

[0092] Examples of polysaccharides include glycosaminoglycans, hyaluronic acid, heparin, low molecular weight heparin or very low molecular weight heparin or derivatives thereof, or sulfated polysaccharides, such as the above-mentioned polysaccharides in polysulfated form, and / or their pharma- ceutically acceptable salts. An example of a pharma-ceutically acceptable salt of polysulfated low molecular weight heparin is enoxaparin sodium. An example of a hyaluronic acid derivative is Hylan G-F20 (Synvisc®), sodium hyaluronate.

[0093] The term "antibody" as used herein refers to an immunoglobulin molecule or an antigen-binding portion thereof. Examples of antigen-binding portions of an immunoglobulin molecule include F(ab) and F(ab')2 fragments that retain the ability to bind to an antigen. An antibody can be a polyclonal antibody, a monoclonal antibody, a recombinant antibody, a chimeric antibody, a deimmunized or humanized antibody, a fully human antibody, a non-human (e.g., murine) antibody, or a single chain antibody. In some embodiments, an antibody has effector function and is capable of fixing complement. In some embodiments, an antibody has reduced or no binding ability to Fc receptors. For example, an antibody can be an isotype or subtype, an antibody fragment, or a mutant that does not support binding to Fc receptors, e.g., with a mutation or deletion of the Fc receptor binding region. The term antibody also includes antigen-binding molecules based on tetravalent bispecific tandem immunoglobulins (TBTI) and / or dual variable region antibody-like binding proteins (CODV) with crossover binding region orientation.

[0094] The term "fragment" or "antibody fragment" refers to a polypeptide (e.g., an antibody heavy and / or light chain polypeptide) derived from an antibody polypeptide molecule that does not contain a full-length antibody polypeptide but that contains at least a portion of a full-length antibody polypeptide that is still capable of binding to an antigen. Antibody fragments include truncated portions of a full-length antibody polypeptide. Antibody fragments useful in the present disclosure include, for example, Fab fragments, F(ab')2 fragments, scFv (single-chain Fv) fragments, linear antibodies, monospecific or multispecific antibody fragments, such as bispecific, trispecific, tetraspecific and multispecific antibodies (e.g., diabodies, triabodies, tetrabodies), monovalent or multivalent antibody fragments, such as bivalent, trivalent, tetravalent and multivalent antibodies, minibodies, chelating recombinant antibodies, tribodies or bibodies, intrabodies, nanobodies, small modular immunopharmaceuticals (SMIPs), binding domain immunoglobulin fusion proteins, camelized antibodies, and VHH-containing antibodies. Additional examples of antigen-binding antibody fragments are known in the art.

[0095] The term "complementarity determining region" or "CDR" refers to short polypeptide sequences in the variable regions of both heavy and light chain polypeptides that are primarily responsible for mediating specific antigen recognition. The term "framework region" refers to amino acid sequences in the variable regions of both heavy and light chain polypeptides that are not CDR sequences and are primarily responsible for maintaining the proper arrangement of the CDR sequences to allow antigen binding. Although the framework region itself typically does not directly participate in antigen binding, as is known in the art, certain residues in the framework region of a particular antibody may be directly involved in antigen binding or may affect the ability of one or more amino acids in the CDR to interact with the antigen.

[0096] Exemplary antibodies are anti-PCSK-9 mAb (eg, alirocumab), anti-IL-6 mAb (eg, sarilumab), and anti-IL-4 mAb (eg, dupilumab).

[0097] Pharmaceutically acceptable salts of any of the APIs described herein are contemplated for use in the drug or medicament in the drug delivery device. Pharmaceutically acceptable salts include, for example, acid addition salts and base salts.

[0098] Those skilled in the art will appreciate that modifications (addition and / or deletions) of the various components of the APIs, formulations, devices, methods, systems, and embodiments described herein may be made without departing from the full spirit and scope of the present disclosure, which includes all such modifications and any and all equivalents thereof.

Claims

1. 1. An auxiliary device configured for releasably attaching to a distal end of a drug delivery device, comprising: The main electronic circuit; a non-contact acceleration sensor located on or in the auxiliary device, the non-contact acceleration sensor being oriented towards the proximal end of the drug delivery device; receiving a signal output from the non-contact acceleration sensor; determining that an outer needle cap of the drug delivery device has been removed based on the signal; a low power processor configured to send a wake-up signal to a main electronic circuit of the auxiliary device in response to determining that an outer needle cap of the drug delivery device has been removed; The auxiliary device.

2. The auxiliary device of claim 1 , further comprising a low power processor readable memory, the memory storing one or more acceleration profiles.

3. 3. The auxiliary device of claim 2, wherein the memory stores software for comparing a signal output from the non-contact acceleration sensor to one or more acceleration profiles.

4. 4. The auxiliary device of claim 2 or claim 3, configured to operate in a machine learning mode in which one or more acceleration profiles are updated based on signals output from a non-contact acceleration sensor.

5. The auxiliary device according to any one of claims 2 to 4, wherein each of the one or more acceleration profiles is associated with a different type of drug delivery device.

6. 6. The auxiliary device of claim 2, wherein a first of the one or more acceleration profiles includes data indicative of a rapid acceleration in the proximal direction followed by a rapid deceleration in the proximal direction.

7. 7. The auxiliary device of claim 6, wherein a first of the one or more acceleration profiles further includes data indicative of a substantially constant velocity between a rapid proximal acceleration and a rapid proximal deceleration.

8. 8. The auxiliary device of claim 6 or claim 7, wherein a first of the one or more acceleration profiles further includes data indicating that the rapid deceleration in the proximal direction continues until the total change in velocity indicates movement in the distal direction.

9. The auxiliary device of any one of claims 2 to 8, wherein a second of the one or more acceleration profiles includes data indicative of a sudden acceleration in the proximal direction followed by an abrupt stop.

10. 10. An auxiliary device according to any preceding claim, wherein the non-contact acceleration sensor is positioned to detect movement of a user's hand as the hand removes the outer needle cap.

11. 11. The method of claim 10, further comprising: providing a position sensor located on or in the auxiliary device, the position sensor being oriented towards the proximal end of the drug delivery device and configured to output a signal indicative of a position and / or orientation of a user's hand and / or the drug delivery device.

2. An auxiliary device as described in claim 1 .

12. An auxiliary device according to any one of the preceding claims, wherein the non-contact acceleration sensor is an electromagnetic reflection sensor.

13. 13. The auxiliary device of claim 12, wherein the non-contact acceleration sensor is an optical sensor or an infrared sensor.

14. 12. An auxiliary device according to claim 10 or claim 11, wherein the position sensor is a passive infrared sensor or an accelerometer.

15. The auxiliary device of any one of claims 1 to 14, further comprising a lock sensor, the lock sensor configured to output a signal indicating whether the auxiliary device is attached to the drug delivery device or not.

16. An auxiliary device according to any one of claims 1 to 15, further comprising a wireless unit adapted to transmit data to one or more external devices.

17. 1. A method of operating an auxiliary device configured to be releasably attached to a distal end of a drug delivery device, comprising: providing a non-contact acceleration sensor located on or in the auxiliary device and directed towards a proximal end of the drug delivery device to output a signal; receiving a signal output from the non-contact acceleration sensor at a low power processor; determining, based on the signal, that an outer needle cap of the drug delivery device has been removed; in response to determining that an outer needle cap of the drug delivery device has been removed, sending a wake-up signal to a main electronic circuit of the auxiliary device; The method comprising:

18. Low power processors: Access one or more acceleration profiles; comparing a signal output from the non-contact acceleration sensor to one or more acceleration profiles; determining whether an outer needle cap of the drug delivery device has been removed based on the comparison; 20. The method of claim 17, further comprising:

19. A system comprising an auxiliary device according to any one of claims 1 to 16 and a drug delivery device.

Images